Acquired Drug Resistance  64 year old female of Hmong ethnicity with long standing, poorly controlled diabetes. No hx TB dx/tx.  11/6/08 CXR “active.

Slides:



Advertisements
Similar presentations
Community Acquired Pneumonia in a Young Diabetic June 21, 2006 John N Landis, MD Chief, Pulmonary Medicine Baystate Medical Center Springfield, MA.
Advertisements

Evaluation Questions Note: If not used for testing purposes, evaluation questions may be used in slide format inserted within or at the end of each module.
Management of Drug-Resistant Tuberculosis Your name Institution/organization Meeting Date International Standard 12.
Nodules and infiltrates
TREATMENT OF TUBERCULOSIS, 2003
‘Resistant infections’ Dr Julian Sutton Consultant in Infectious Diseases & Medical Microbiology.
Case Discussion: TB in Pregnancy December 15, 2010 E. Jane Carter, M.D.
Case discussion Michael Gardam University Health Network.
Case of MDR-TB from Haiti Christopher Kovacs MD Infectious Disease Fellow Cleveland Clinic.
Sheboygan County 2013 Sandy Muesegades, RN – Public Health Nurse.
Clinical Case Female, 27 years of age 3 rd year Internal Medicine resident at the Mexicali General Hospital Never smoked; does not ingest alcoholic beverages.
1 Constructing a regimen Session 5. USAID TB CARE II PROJECT Principles of designing an MDR-TB treatment regimen Include at least four second-line anti-TB.
Module 3: Drug-Resistant TB. Learning Objectives Describe how drug resistance emerges Explain the difference between primary and secondary resistance.
Unit 10 Treating the Dually Infected Patient: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.
TB. Areas of Concern TB cases continue to be reported in every state Drug-resistant cases reported in almost every state Estimated million persons.
Clinical Pharmacy.  Tuberculosis is caused by M. tuberculosis, an aerobic, non–spore-forming bacillus that resists decolorization by acid alcohol after.
TB Case Study Pulmonary TB in US-born Client. Overview  60-year old white male  Lifelong Madison resident, lives with wife and dog  Comorbidities:
Christoph Lange & Giovanni Sotgiu Principles of designing a TB and MDR-TB drug regimen.
 Pulmonary Tuberculosis BY: MOHAMED HUSSEIN. Cause  Caused by Mycobacterium tuberculosis (M. tuberculosis)  Gram (+) rod (bacilli). Acid-fast  Pulmonary.
Hepatotoxicity. Overview INH, Rifampin, and PZA all are associated with DILI (drug-induced liver injury) Only one case of DILI has been reported for Ethambutol.
HAIVN Harvard Medical School AIDS Initiative in Vietnam
Unit 7 Treatment of TB: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.
Introduction to the Forms Julie Tomaro, BSN Washington State Department of Health INTERJURISDICTIONAL TB NOTIFICATION (IJN) TRANSFER AND FOLLOW-UP FORMS.
Tuberculosis Research of INA-RESPOND on Drug-resistant
TB 101 Part II Brenda Mayes, R. N. March TREATMENT TB DISEASE MDR XDR LATENT TB INFECTION.
Treatment of Tuberculosis: New Case Case Studies Module 7A2 – March 2010.
Wisconsin State Laboratory of Hygiene. WISCONSIN STATE LABORATORY OF HYGIENE Case Study Youngmi Kim, MS, ASCP(M) Senior Microbiologist, Wisconsin State.
Management of Tuberculosis: A Surgical Perspective Alfred Lardizabal, MD Associate Professor Division of Pulmonary and Critical Care Medicine UMDNJ-NJ.
Clinicopathologic Conference Advanced Update in HIV Medicine and Clinical Research October 1, 2009 Tammy M. Meyers, BA, MBBCh (WITS), FCPaed (SA), Mmed,
Revising the WHO TB Treatment Guidelines Process and new recommendations Malgosia Grzemska Matteo Zignol Stop TB Department World Health Organization DEWG.
Infectious Conditions of the Lower Respiratory Tract.
By: Michelle Russell.  To become familiar with the disease process of TB Transmission symptoms Precautions  Nursing Diagnoses  Interventions.
NYU Medical Grand Rounds Clinical Vignette Verity Schaye, MD PGY-3 September 15, 2010 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
Diagnostic Tests Chest x-ray –Patchy or nodular infiltrate –Apical or sub-apical posterior aspects of UPPER LOBES (or superior segment of lower.
Kaiser Oakland Contact Investigation CTCA Conference May 6 th, 2010 Tara Greenhow, MD Pediatric Infectious Diseases Kaiser Permanente San Francisco.
NAAT Is it Time for a New Option in California?. Background CDC 2009 guidelines recommend NAAT for each patient with suspected TB for whom the test result.
Clinical Case Female, 27 years of age Female, 27 years of age 3 rd year Internal Medicine resident at the Mexicali General Hospital 3 rd year Internal.
Tuberculosis August 17, 2010 Tuberculosis Mycobacterium tuberculosis – Fastidious, aerobic, acid-fast bacillus Tremendous increase in incidence over.
Unit 11 Drug Resistance and MDR-TB: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.
Pulmonary TB aspects Etienne Leroy Terquem – Pierre L’Her SPI / ISP Soutien Pneumologique International / International Support for Pulmonology Nodule.
MUNEZ. 3 months PTA, patient had fever, cough and colds. Consult done at a local health center where she was given amoxicillin for 1 week with noted resolution.
Patient with Presumptive TB HIV Status PositiveNegative % Empiric Tx of Patients with Active TB % Empiric Tx of TB-Symptomatic Patients without True TB.
By: Mpho Kontle and Topo Moses. Introduction & Etiology Multi-drug-resistant tuberculosis (MDR-TB) is defined as tuberculosis that is resistant to at.
L.A. County Public Health Partnering with the Private Community to Control TB Myrna Mesrobian, MD, MPH.
Tuberculosis By Fion Kung. Objective  Describe tuberculosis  Describe sigh and symptoms of tuberculosis  Describe the nursing diagnosis for tuberculosis.
Case Study Cloete van Vuuren ID Physician. 50 year old male Abscess over L parotid gland Cryptoccal meningitis 2010 PTB 2010 – completed 6/12 of Rx Stopped.
LEARNING MODULE TITLE SUBTITLE. HISTORY OF PRESENT ILLNESS An 18 year-old woman with no past medical history and no known risks for TB presents with several.
Anti-tuberculosis drugs. First-line drugs Isoniazid (INH or H) Rifampin (RMP or R) Ethambutol (EMB or E) Pyrazinamide (PZA or Z)
Treatment Regimens for Pulmonary Tuberculosis Caused by Drug- Susceptible Organisms Initial PhaseContinuation Phase RegimenDrugs Interval and Doses (Minimal.
Ward 5D Linda Iskandar 1. Patient MR From Nepal, has been in Australia for 2 years on a dependent student visa studying nursing. Presenting complaints.
Case Discussion 2 - TB IN CHILDREN by Dr. Jeyaseelan P. Nachiappan & Dr. Suryati Adnan 1 Picture of CPG Cover.
Therapeutics 3 Tutoring Exam 4 February 27 th, 2016 Lisa Hayes
“Monitoring Systemic Lupus Erythematosus” Andres Quiceno, MD Presbyterian Hospital of Dallas.
Drug Resistant Tuberculosis
Management of the Newborn When Maternal TB Suspected
Management of Tuberculosis: A Surgical Perspective
Treatment of TB Disease
This is an archived document.
Treatment algorithm for tuberculosis
Drug Resistant (DR) TB (Back to Basics)
بسم الله الرحمن الرحيم.
Marie Turner, M.D. Jo-Ann Keegan, R.N., M.S.N.
STREAM (Evaluation of a Standardised Treatment Regimen of Anti-tuberculosis Drugs for Patients with Multidrug-resistant Tuberculosis) treatment regimens.
Hidalgo County Hospital TB Outbreak Investigation
Tb: Screening & Diagnosis (1)
CASE HOLDING FOR PMDT.
Tuberculosis Control Program
DR SAUMU WAYUWA KPA ANNUAL SCIENTIFIC CONFERENCE 2019
Diversity of resistant and susceptible isolates.
Fig. 1. Antituberculosis drug resistance rate (%) and pattern in sanatoria of North Korea: (A) patients (n = 489) in all sanatoria analyzed in this study,
Presentation transcript:

Acquired Drug Resistance  64 year old female of Hmong ethnicity with long standing, poorly controlled diabetes. No hx TB dx/tx.  11/6/08 CXR “active processes in both upper lobes that are most likely inflammatory in nature”  Sputa AFB smear negative  Plan was to begin empiric treatment after pulmonary consult  Referred to pulmonologist, but failed appointments, no treatment  Culture negative, no treatment

Acquired Drug Resistance  Aug 2009 she collapsed in her home  Arrived at hospital via ambulance, unconscious  Transferred to Doctor’s Hospital in Modesto  Reportedly had cough since the November 2008 exam  Pt reports that she is now “skinny”, implying weight loss, but none documented

Acquired Drug Resistance  8/29/09 - Heavily smear (+) with bilateral infiltrates on CXR  8/31/09 - Began RIPE  Initial isolate pan-sensitive  10/2/09 - EMB discontinued  11/6/09 - PZA discontinued  10/8/09 - Smears become negative  Cultures remain positive

Acquired Drug Resistance  1/12/10 - CXR “Progressive bilateral upper lobe infiltrates”  1/27/10 - Smears become 2+ AFB positive  Subsequently, it was learned that she had begun vomiting (start date unclear) shortly after DOT worker left each day  She did not report this for several months

Acquired Drug Resistance  Repeat DST results show: Resistance to INH, Rif Resistance to INH, Rif Sensitive to EMB, PZA, ETA, CM, AK & LFX Sensitive to EMB, PZA, ETA, CM, AK & LFX

Acquired Drug Resistance  Hospitalized & expanded regimen started: Amikacin, 750 mg 5x wk via PICC (later lowered) Amikacin, 750 mg 5x wk via PICC (later lowered) Moxifloxacin, 400 mg po qd Moxifloxacin, 400 mg po qd Ethambutol, 1200 mg po qd Ethambutol, 1200 mg po qd PZA, 1250 mg po qd PZA, 1250 mg po qd Linezolid, 600 mg po qd Linezolid, 600 mg po qd B6, 100 mg po qd B6, 100 mg po qd Zofran for vomiting Zofran for vomiting  Baseline color vision and hearing OK. Glucose levels, LFTs, and renal functions were excellent throughout hospital stay

Therapeutic Drug Levels (MFX collected 4/19/10, all others 4/23/10) DrugDose 2 hr level 6 hr level Ref Range EMB 1200 mg po qd hr 2-6 mcg/ml PZA 1250 mg po qd hr mcg/ml MFX 400 mg po qd hr 3-5 mcg/ml No 6 hr range LNZ 600 mg po qd hr mcg/ml AK 550 mg IV 5d/wk 20.8 Cmax Cmax mcg/ml